ME-401 clinical trials
Also written ME-401, Zandelisib and PWT-143.
How each study uses ME-401 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
9 studies that test it; most in 2019 (2)
| Year | Studies |
|---|---|
| 2015 | 1 |
| 2016 | 1 |
| 2019 | 2 |
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 1 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 2
MEI Pharma, Inc. (5) · Kyowa Kirin Co., Ltd. (2) · Deepa Jagadeesh (1) · Jacob Soumerai, MD (1)
Related medicines
As reviewed, each with the page that says it.
- One of Protein Kinase Inhibitors source
Studies
Open first, then newest update. How each study uses ME-401 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 9
- Study of ME-401 in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma (NHL)Active, not recruitingPhase 2Kyowa Kirin Co., Ltd.NCT04533581Written as ME-401How we know
- Study of ME-401 in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin's LymphomaCompletedPhase 1Kyowa Kirin Co., Ltd.NCT03985189Written as ME-401How we know
- ME-401 and R-CHOP in Newly Diagnosed Diffuse Large B-Cell LymphomaTerminatedPhase 1/2Deepa JagadeeshNCT04517435Written as ME-401How we know
- Zandelisib (ME-401) in Subjects With Follicular Lymphoma or Marginal Zone Lymphoma After Failure of Two or More Prior Therapies (TIDAL)TerminatedPhase 2MEI Pharma, Inc.NCT03768505Written as Zandelisib (ME-401)How we know
- Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL)TerminatedPhase 3MEI Pharma, Inc.NCT04745832Written as ZandelisibHow we know
- Zandelisib + Tazemetostat in R/R Follicular LymphomaWithdrawnPhase 1/2Jacob Soumerai, MDNCT05604417Written as ZandelisibHow we know
- A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's LymphomaTerminatedPhase 1MEI Pharma, Inc.NCT02914938Written as ME-401How we know
- Rituximab Plus Venetoclax in Combination With Zandelisib in Subjects With CLLWithdrawnPhase 2MEI Pharma, Inc.NCT05209308Written as ZandelisibHow we know
- Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Various Formulations and Doses of PWT-143CompletedPhase 1MEI Pharma, Inc.NCT02521389Written as PWT-143How we know